{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:40:35Z","timestamp":1792798835849,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.oret.2026.10.008","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:16:15Z","timestamp":1792797375000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Oral Belzutifan for Retinal Capillary Hemangioblastomas in von Hippel-Lindau Disease"],"prefix":"10.1016","author":[{"given":"Marco H.","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa T.","family":"Thavikulwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Agr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Indurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Emamverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiarn\u00e1n D.L.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.oret.2026.10.008_bib1","article-title":"von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance","volume":"65","author":"Louise","year":"2022","journal-title":"Eur J Med Genet"},{"issue":"2","key":"10.1016\/j.oret.2026.10.008_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3928\/23258160-20200129-07","article-title":"Von Hippel-Lindau Syndrome Phenotype With Prominent Vitreoretinal Neovascularization Treated With Early PPV: A Case Series and Literature Review","volume":"51","author":"Zubair","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"10.1016\/j.oret.2026.10.008_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","article-title":"A Review of Von Hippel-Lindau Syndrome","volume":"4","author":"Varshney","year":"2017","journal-title":"J Kidney Cancer VHL"},{"issue":"10","key":"10.1016\/j.oret.2026.10.008_bib4","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0161-6420(02)01177-6","article-title":"Treatment of retinal capillary hemangioma","volume":"109","author":"Singh","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.10.008_bib5","first-page":"367","article-title":"Von Hippel-Lindau disease: the recognition and treatment of early angiomatosis retinae and the use of cryosurgery as an adjunct to therapy","volume":"68","author":"Welch","year":"1970","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"1","key":"10.1016\/j.oret.2026.10.008_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.oret.2016.08.004","article-title":"Laser Photocoagulation for Peripheral Retinal Capillary Hemangioblastoma in von Hippel-Lindau Disease","volume":"1","author":"Krivosic","year":"2017","journal-title":"Ophthalmol Retina"},{"issue":"22","key":"10.1016\/j.oret.2026.10.008_bib7","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.oret.2026.10.008_bib8","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-22-1054","article-title":"FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors","volume":"28","author":"Fallah","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.oret.2026.10.008_bib9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.ophtha.2024.05.024","article-title":"Oral Hypoxia-Inducible Factor 2alpha Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study","volume":"131","author":"Wiley","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.10.008_bib10","article-title":"Belzutifan-induced regression of retinal capillary hemangioblastoma: A case-series","volume":"33","author":"Ercanbrack","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"10.1016\/j.oret.2026.10.008_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/24741264241309684","article-title":"Belzutifan as the Primary Treatment of Bilateral Juxtapapillary Retinal Hemangioblastoma in a Patient With Von Hippel-Lindau Disease","volume":"9","author":"Dameron","year":"2025","journal-title":"J Vitreoretin Dis"},{"issue":"1","key":"10.1016\/j.oret.2026.10.008_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/ICB.0000000000001516","article-title":"Belzutifan for Treatment of Giant Retinal Hemangioblastoma with Extrascleral Extension Associated with Von Hippel-Lindau Syndrome","volume":"19","author":"Cotton","year":"2025","journal-title":"Retin Cases Brief Rep"},{"issue":"7","key":"10.1016\/j.oret.2026.10.008_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"3","key":"10.1016\/j.oret.2026.10.008_bib14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/aos.12555","article-title":"Clinical verification of the formula of Bennett et al. (1994) of determining the size of retinal features by fundus photography","volume":"93","author":"Knaapi","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2026.10.008_bib15","doi-asserted-by":"crossref","unstructured":"Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlang New York; 2016.","DOI":"10.1007\/978-3-319-24277-4_9"},{"issue":"8","key":"10.1016\/j.oret.2026.10.008_bib16","article-title":"Oral HIF-2\u03b1 inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease","volume":"62","author":"Wiley","year":"2021","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"10","key":"10.1016\/j.oret.2026.10.008_bib17","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/IAE.0b013e318182fc41","article-title":"Spontaneous regression of a retinal capillary hemangioma","volume":"28","author":"Molina","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.10.008_bib18","article-title":"Response of a von Hippel-Lindau-associated optic nerve hemangioblastoma to belzutifan","author":"Meade","year":"2024","journal-title":"Retin Cases Brief Rep"},{"issue":"3","key":"10.1016\/j.oret.2026.10.008_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000539434","article-title":"Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature","volume":"10","author":"Jamshidi","year":"2024","journal-title":"Ocul Oncol Pathol"},{"issue":"11","key":"10.1016\/j.oret.2026.10.008_bib20","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3928\/23258160-20240607-01","article-title":"Significant Improvement in Retinal Capillary Hemangioblastoma With Belzutifan","volume":"55","author":"Mohammadi","year":"2024","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"10.1016\/j.oret.2026.10.008_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/ICB.0000000000001376","article-title":"Two Cases of Von Hippel-Lindau Syndrome-Associated Retinal Hemangioblastoma Treated with Belzutifan","volume":"18","author":"Grimes","year":"2024","journal-title":"Retin Cases Brief Rep"},{"issue":"6","key":"10.1016\/j.oret.2026.10.008_bib22","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/j.jcjo.2024.05.025","article-title":"Belzutifan as the first-line treatment for a challenging von Hippel-Lindau-related retinal hemangioblastoma: successful treatment of a case and review of the literature","volume":"59","author":"Aykut","year":"2024","journal-title":"Can J Ophthalmol"},{"issue":"5","key":"10.1016\/j.oret.2026.10.008_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000003973","article-title":"Successful Treatment Response of a Juxtapapillary Retinal Capillary Hemangioblastoma Due to von Hippel-Lindau Syndrome with Belzutifan in a Pediatric Patient","volume":"44","author":"Mustafi","year":"2024","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.10.008_bib24","article-title":"Very rapid response to belzutifan of VHL-related intracranial and retinal hemangioblastomas","volume":"42","author":"Pagliara","year":"2026","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"10.1016\/j.oret.2026.10.008_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31371","article-title":"Pediatric patients with von Hippel-Lindau and hemangioblastomas treated successfully with belzutifan","volume":"72","author":"Duan","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.oret.2026.10.008_bib26","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1016\/j.jcjo.2025.08.014","article-title":"One-week response of retinal hemangioblastomas to oral belzutifan","volume":"60","author":"Attaseth","year":"2025","journal-title":"Can J Ophthalmol"},{"issue":"5","key":"10.1016\/j.oret.2026.10.008_bib27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/ICB.0000000000001452","article-title":"Successful Treatment of Von Hippel-Lindau Disease-Associated Retinal Capillary Hemangioblastoma with Belzutifan in a Pediatric Patient","volume":"18","author":"Jones","year":"2024","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.oret.2026.10.008_bib28","article-title":"The effect of oral belzutifan on retinal hemangioblastomas in von Hippel-Lindau syndrome","author":"Stephenson","year":"2025","journal-title":"Can J Ophthalmol"},{"issue":"12","key":"10.1016\/j.oret.2026.10.008_bib29","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000002555","article-title":"VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects","volume":"39","author":"Aronow","year":"2019","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.oret.2026.10.008_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.15586\/jkcvhl.v12i3.425","article-title":"Long-term Safety and Efficacy of Belzutifan in Von Hippel-Lindau Syndrome: A VHL Coordinating Care Center Experience","volume":"12","author":"do Amaral","year":"2025","journal-title":"J Kidney Cancer VHL"},{"issue":"9","key":"10.1016\/j.oret.2026.10.008_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf274","article-title":"The safety profile of belzutifan in renal tumors: real-world data from a tertiary academic center","volume":"30","author":"Winer","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.oret.2026.10.008_bib32","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Accessed September 29, 2026, https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"issue":"7","key":"10.1016\/j.oret.2026.10.008_bib33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3928\/23258160-20160707-06","article-title":"Posterior Segment Distortion in Ultra-Widefield Imaging Compared to Conventional Modalities","volume":"47","author":"Nicholson","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2026.10.008_bib34","unstructured":"Drugs.com. Welireg Prices, Coupons, Copay Cards & Patient Assistance. Accessed August 10, 2026, https:\/\/www.drugs.com\/price-guide\/welireg"},{"key":"10.1016\/j.oret.2026.10.008_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251379708","article-title":"Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China","volume":"17","author":"Ding","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.oret.2026.10.008_bib36","unstructured":"Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Belzutifan (Welireg): CADTH Reimbursement Recommendation. 2023."}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026005427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026005427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:16:19Z","timestamp":1792797379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026005427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S2468653026005427"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.10.008","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Oral Belzutifan for Retinal Capillary Hemangioblastomas in von Hippel-Lindau Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Academy of Ophthalmology, Inc.","name":"copyright","label":"Copyright"}]}}